MedTrace Logo

Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment

NCT00813722 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2008-12-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the importance of providing guidelines to patients via active telephone calls in blood pressure control and in the discontinuation of treatment among hypertensive patients. Hypertensives (N = 354) who could receive telephone calls to be reminded of the dates of their medical appointments and to be instructed about hypertension were distributed into two groups: a) "uncomplicated" - hypertensives with no other concurrent diseases; and b) "complicated" - severe hypertensives (mean diastolic ≥ 110 mm Hg with or without medication) or comorbidities. All patients, except those excluded (n=44), were open block randomized to follow two treatment regimens: "traditional" or "current" and to receive active telephone calls ("phone calls" group) or not to receive telephone calls ("no phone calls" group).

Conditions

  • Blood Pressure

Interventions

BEHAVIORAL

phone call

patients received or not phone calls to give orientation abou treatment

DRUG

amlodipine (calcium chanel blocker) and losartan (at1 antagonist)

2,5 mg tid and 25 mg tid

DRUG

atenolol (beta blocker) and hydrochlorothiazide (diuretic)

25 mg tid and 12,5 mg tid

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Decio Mion Jr, MD · University of Sao Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Primary Completion
2009-01-31
Completion
2009-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813722 on ClinicalTrials.gov